Bioxytran, Inc.
BIXT · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $8 | $8 | $4 | $0 |
| Gross Profit | -$8 | -$8 | -$4 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $112 | $1,149 | $978 | $2,014 |
| G&A Expenses | $1,168 | $2,473 | $1,156 | $2,201 |
| SG&A Expenses | $1,168 | $2,671 | $1,156 | $2,201 |
| Sales & Mktg Exp. | $0 | $198 | $0 | $0 |
| Other Operating Expenses | $943 | $0 | $4 | $0 |
| Operating Expenses | $2,223 | $3,820 | $2,138 | $4,214 |
| Operating Income | -$2,223 | -$3,820 | -$2,134 | -$4,214 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$157 | -$550 | -$523 | -$314 |
| Pre-Tax Income | -$2,380 | -$4,370 | -$2,657 | -$4,528 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2,367 | -$4,280 | -$2,464 | -$4,345 |
| % Margin | – | – | – | – |
| EPS | -0.017 | -0.032 | -0.021 | -0.041 |
| % Growth | 46.4% | -49.1% | 47.7% | – |
| EPS Diluted | -0.017 | -0.032 | -0.021 | -0.041 |
| Weighted Avg Shares Out | 138,599 | 134,225 | 115,139 | 106,252 |
| Weighted Avg Shares Out Dil | 138,599 | 134,224 | 115,139 | 106,252 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $770 | $542 | $520 | $314 |
| Depreciation & Amortization | $8 | $8 | $4 | $4,214 |
| EBITDA | -$2,223 | -$3,820 | -$2,134 | $0 |
| % Margin | – | – | – | – |